Versant Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Versant Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-54	Closed	-$1K	–	1628
2020 Q3	$1K	Buy	54 +21	+64%	+$447	﹤0.01%	1263
2020 Q2	$0	Sell	33 -13	-28%	-$221	﹤0.01%	1665
2020 Q1	$0	Buy	+46	New	+$1.18K	﹤0.01%	1850

Versant Capital Management's AIMT Position: Q4 2020 in Review

Versant Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 54 shares — an estimated $1K sold.

Versant Capital Management first reported a position in AIMT in Q1 2020 and held it in 3 quarters. The position peaked at $1K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Versant Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Versant Capital Management sold 54 Aimmune Therapeutics shares in Q4 2020, an estimated $1K.
Versant Capital Management first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 3 quarters.
Versant Capital Management's Aimmune Therapeutics position peaked at $1K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Versant Capital Management's 13F filing for Q4 2020, filed 8 Feb 2021.